Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

STEMOX Unraveling redox regulation in cancer stem cells as a potential therapeutic target for breast cancer

Coordinator
Universita Degli Studi Di Torino, Italy
Runs
1 April 2023 to 31 March 2025
Status
Running
EU funding
€173k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101068377

What the project is doing

In the project's own words, from its summary on CORDIS.

ABSTRACT Breast cancer (BC) is the most frequently diagnosed cancer and the first cause of cancer death in women worldwide. In many tumors, including BC, there is a population of cancer stem cells (CSCs) characterized for unlimited self-renewal and being resistant to conventional cancer therapies eventually leading to tumor relapses and metastases. Breast CSCs (BCSCs) show high cellular plasticity and are capable of shifting between a proliferative epithelial-like (E) state and a quiescent mesenchymal-like (M) state.

This plasticity of BCSCs facilitates their ability to initiate and grow primary tumors, invade the basement membrane, traverse tissue vasculature, and ultimately colonize distant organs to form clinically significant metastases. It has been recently proposed that redox regulation might play a significant role in BCSCs plasticity and aggressiveness. We hypothesize that the redox-regulated BCSC plasticity and the highly oxidative metabolism of E-BCSCs might be a vulnerability that could be exploited as a novel BC therapy.

We aim to characterize BCSCs in terms of individual ROS production, transducing our breast cancer patient-derived organoids (PDOs) collection with genetically-encoded redox sensors. We will treat breast cancer PDOs with conventional chemotherapy and inhibitors of PI3K to study changes in redox signaling occurring in the tumor. Finally, we will attempt to target these cells and modulate their redox regulation in order to differentiate and eliminate them.

We expect to better understand the redox-regulation of BCSCs, to subsequently modulate BCSC redox state to target and eliminate these cells, increasing conventional therapy effectiveness and decreasing the minimal residual disease and cancer spread in BC patients, contributing to overall survival.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di TorinoTorinoItalyCoordinator
Universitat Des SaarlandesSaarbruckenGermanyAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI